Replies to post #516716 on Anavex Life Sciences Corp (AVXL)

[jav0033]

All it matters is CHMP rejected Blarcamesineee TWICE. 
Management is hiding critical information apparently. Missling is a COWARD.

[WilliamMunny]

You might go ahead and ask whichever A1 you selected to tell us how much efficacy LEQEMBI (Lecanemab) demonstrated in reducing cognitive decline for women, who represent about two-thirds of all Alzheimer's patients.